Special Issue

New Aspects of Targeting Cancer Metabolism in Therapeutic Approach

Message from the Guest Editor

Recently, cancer therapy has made a significant change by heading toward regulating the immune system, despite the fact that most cancers are not induced by mutation of the immune system. This implies a very important shift in focus, from what causes cancer to how we can cure cancer. The real matter resides in the question of how we can distinguish cancer cells from normal cells. Cancer metabolism is quickly becoming a major drug target for the treatment of a variety of cancers. Cancer-specific metabolic inhibitor enasidenib has been approved for acute myeloid leukemia therapy (2017) by the US FDA and will likely continue to expand. A series of studies on cancer specific metabolic dependency may find a use for the list of metabolic inhibitors as therapeutic agents. That will be the ultimate answer for how we can kill only cancer cells when systemically mixed with normal cells. This Special Issue focuses on the connection between cancer-specific metabolism and its possibility as a therapeutic target, with an emphasis on novel inhibitors and new therapeutic possibilities targeting metabolic pathways.

Guest Editor

Dr. Soo-Youl Kim

National Cancer Center, Gyeonggi, Goyang, Korea

Deadline for manuscript submissions

closed (31 March 2022)

Cells

an Open Access Journal by MDPI

Impact Factor 5.1
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/30919

Cells
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells

Cells

an Open Access Journal by MDPI

Impact Factor 5.1
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/cells

MDPI

About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Prof. Dr. Alexander E. Kalyuzhny
Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2024).